I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 87.84 M, beating the estimate of USD 80.06 M.
EPS: As of FY2026 Q2, the actual value is USD 0.08.
EBIT: As of FY2026 Q2, the actual value is USD 1.804 M.
Omada Health, Inc. reported its financial results for the three and six months ended June 30, 2026.
Second Quarter 2026 Financial Highlights
Omada Health, Inc. reported total revenue of $88 million for the second quarter ended June 30, 2026, marking a 43% increase compared to $61 million in Q2 2025. This was driven by service revenue of $80.692 million (up from $56.960 million in Q2 2025) and hardware revenue of $7.143 million (up from $4.411 million in Q2 2025). The company achieved a GAAP gross margin of 73% in Q2 2026, an increase from 66% in Q2 2025, and a non-GAAP gross margin of 74%, up from 68% in Q2 2025. Net income for the quarter was $5 million, a significant improvement from a net loss of - $5 million in Q2 2025. Adjusted EBITDA reached $11 million, compared to an adjusted EBITDA loss of - $0.2 million in the prior year period. Operating income was $3.549 million in Q2 2026, compared to an operating loss of - $4.344 million in Q2 2025. Total operating expenses were $60.238 million in Q2 2026, up from $44.650 million in Q2 2025. Cash and cash equivalents stood at $222 million.
Six Months Ended June 30, 2026 Financial Highlights
For the six months ended June 30, 2026, total revenue was $165.883 million, compared to $116.334 million for the same period in 2025. Gross profit for the six-month period was $112.480 million, up from $72.206 million in 2025. Operating loss improved to - $1.232 million for the six months ended June 30, 2026, from - $12.740 million in the prior year. Net income for the six months was $2.324 million, a notable improvement from a net loss of - $14.759 million in 2025. Total operating expenses for the six months were $113.712 million, compared to $84.946 million in 2025.
Cash Flow
Net cash used in operating activities for the six months ended June 30, 2026, was - $7.827 million, an improvement from - $13.260 million in the same period of 2025. Free cash flow for the six months ended June 30, 2026, was - $11.048 million, compared to - $15.759 million in the prior year period.
Operational Metrics
Total Members increased by 45% year over year. The trailing twelve-month revenue per total member grew approximately 2% year over year to $284. Omada Health, Inc. broadened its partnership with Health Care Services Corporation (HCSC), extending programs to an additional 1.5 million covered lives. The company also launched the first deployment of its cholesterol management offering and closed its first customer for the prescribing program, which is expected to yield revenue in 2027.
Leadership Transition
Omada Health, Inc. announced a leadership transition, effective January 1, 2027. Sean Duffy, the current Chief Executive Officer, will transition to Executive Chairman of the Board of Directors, and Wei-Li Shao, the current President, will succeed Mr. Duffy as the Chief Executive Officer. Jeryl Hilleman was appointed as Lead Independent Director, also effective January 1, 2027.
Financial Outlook
For the year ending December 31, 2026, Omada Health, Inc. expects revenue in the range of $334 million to $340 million, an increase from the prior guidance of $322 million to $330 million. This updated revenue guidance midpoint represents 30% growth compared to 2025. Adjusted EBITDA is projected to be in the range of $21 million to $27 million, with the midpoint representing a fourfold increase compared to 2025, up from the previous range of $14 million to $20 million.